Mexiletine: a new type I antiarrhythmic agent

Area of Science:

• Pharmacology
• Cardiology
• Clinical Therapeutics

Background:

• Mexiletine is a type I antiarrhythmic agent, structurally related to lidocaine.
• It possesses good oral bioavailability due to minimal first-pass metabolism.
• Potential side effects include neurologic, cardiac, and gastrointestinal issues.

Purpose of the Study:

• To evaluate the efficacy and disposition of mexiletine in treating cardiac arrhythmias.
• To explore mexiletine's role in combination therapy for refractory ventricular tachycardia.
• To assess the clinical utility and therapeutic drug monitoring of mexiletine.

Main Methods:

• Review of mexiletine's pharmacokinetic properties (bioavailability, volume of distribution, half-life).
• Assessment of mexiletine's efficacy in premature ventricular contractions and drug-refractory inducible ventricular tachycardia.
• Evaluation of mexiletine's effectiveness as monotherapy versus combination therapy.

Main Results:

• Mexiletine is comparable to traditional antiarrhythmics for premature ventricular contractions.
• Mexiletine monotherapy is generally ineffective for drug-refractory inducible ventricular tachycardia.
• Combination therapy with mexiletine yields better responses in difficult arrhythmias.
• Mexiletine disposition may be affected by heart failure, liver disease, and renal dysfunction.
• Correlation between mexiletine serum concentrations and efficacy/toxicity is poor.

Conclusions:

• Mexiletine is a viable option for certain arrhythmias, particularly when combined with other agents.
• Its utility in managing refractory ventricular tachycardia requires further investigation, especially in combination therapy.
• The precise role of mexiletine in clinical practice and therapeutic drug monitoring remains to be clearly defined.